Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants
The continuous emergence of highly immune-evasive SARS-CoV-2 variants has challenged vaccine efficacy. A vaccine that can provide broad protection is desirable. We evaluated the immunogenicity of a series of monovalent and bivalent adenovirus-vectored vaccines containing the spikes of Wildtype (WT),...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2387447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168113944854528 |
|---|---|
| author | Hengchun Li Chenchen Yang Li Yin Wenming Liu Zhengyuan Zhang Bo Liu Xinxin Sun Wenhao Liu Zihan Lin Zijian Liu Ping He Ying Feng Chunhua Wang Wei Wang Suhua Guan Qian Wang Ling Chen Pingchao Li |
| author_facet | Hengchun Li Chenchen Yang Li Yin Wenming Liu Zhengyuan Zhang Bo Liu Xinxin Sun Wenhao Liu Zihan Lin Zijian Liu Ping He Ying Feng Chunhua Wang Wei Wang Suhua Guan Qian Wang Ling Chen Pingchao Li |
| author_sort | Hengchun Li |
| collection | DOAJ |
| description | The continuous emergence of highly immune-evasive SARS-CoV-2 variants has challenged vaccine efficacy. A vaccine that can provide broad protection is desirable. We evaluated the immunogenicity of a series of monovalent and bivalent adenovirus-vectored vaccines containing the spikes of Wildtype (WT), Beta, Delta, Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.5, BQ.1.1, and XBB. Vaccination in mice using monovalent vaccines elicited the highest neutralizing titers against each self-matched strain, but against other variants were reduced 2− to 73-fold. A bivalent vaccine consisting of WT and BA.5 broadened the neutralizing breadth against pre-Omicron and Omicron subvariants except XBB. Among bivalent vaccines based on the strains before the emergence of XBB, a bivalent vaccine consisting of BA.2 and BA.5 elicited the most potent neutralizing antibodies against Omicron subvariants, including XBB. In mice primed with injected WT vaccine, intranasal booster with a bivalent vaccine containing XBB and BA.5 could elicit broad serum and respiratory mucosal neutralizing antibodies against all late Omicron subvariants, including XBB. In mice that had been sequentially vaccinated with WT and BA.5, intranasal booster with a monovalent XBB vaccine elicited greater serum and mucosal XBB neutralizing antibodies than bivalent vaccines containing XBB. Both monovalent and bivalent XBB vaccines induced neutralizing antibodies against EG.5. Unlike the antibody response, which is highly variant-specific, mice receiving either monovalent or bivalent vaccines elicited comparable T-cell responses against all variants. Furthermore, intranasal but not intramuscular booster induced antigen-specific lung resident T cells. This study provides insights into the design of the COVID-19 vaccine and vaccination strategies. |
| format | Article |
| id | doaj-art-3d006198f7bf443e9016caa40d1e496b |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-3d006198f7bf443e9016caa40d1e496b2025-08-20T02:21:03ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2024.2387447Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variantsHengchun Li0Chenchen Yang1Li Yin2Wenming Liu3Zhengyuan Zhang4Bo Liu5Xinxin Sun6Wenhao Liu7Zihan Lin8Zijian Liu9Ping He10Ying Feng11Chunhua Wang12Wei Wang13Suhua Guan14Qian Wang15Ling Chen16Pingchao Li17State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaSchool of Life Sciences, Jilin University, Changchun, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaGuangzhou nBiomed Ltd., Guangzhou, People’s Republic of ChinaGuangzhou Bio-island Laboratory, Guangzhou, People’s Republic of ChinaGuangzhou nBiomed Ltd., Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaThe continuous emergence of highly immune-evasive SARS-CoV-2 variants has challenged vaccine efficacy. A vaccine that can provide broad protection is desirable. We evaluated the immunogenicity of a series of monovalent and bivalent adenovirus-vectored vaccines containing the spikes of Wildtype (WT), Beta, Delta, Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.5, BQ.1.1, and XBB. Vaccination in mice using monovalent vaccines elicited the highest neutralizing titers against each self-matched strain, but against other variants were reduced 2− to 73-fold. A bivalent vaccine consisting of WT and BA.5 broadened the neutralizing breadth against pre-Omicron and Omicron subvariants except XBB. Among bivalent vaccines based on the strains before the emergence of XBB, a bivalent vaccine consisting of BA.2 and BA.5 elicited the most potent neutralizing antibodies against Omicron subvariants, including XBB. In mice primed with injected WT vaccine, intranasal booster with a bivalent vaccine containing XBB and BA.5 could elicit broad serum and respiratory mucosal neutralizing antibodies against all late Omicron subvariants, including XBB. In mice that had been sequentially vaccinated with WT and BA.5, intranasal booster with a monovalent XBB vaccine elicited greater serum and mucosal XBB neutralizing antibodies than bivalent vaccines containing XBB. Both monovalent and bivalent XBB vaccines induced neutralizing antibodies against EG.5. Unlike the antibody response, which is highly variant-specific, mice receiving either monovalent or bivalent vaccines elicited comparable T-cell responses against all variants. Furthermore, intranasal but not intramuscular booster induced antigen-specific lung resident T cells. This study provides insights into the design of the COVID-19 vaccine and vaccination strategies.https://www.tandfonline.com/doi/10.1080/22221751.2024.2387447AdenovirusCOVID-19Omicronmonovalent vaccinebivalent vaccineimmunogenicity |
| spellingShingle | Hengchun Li Chenchen Yang Li Yin Wenming Liu Zhengyuan Zhang Bo Liu Xinxin Sun Wenhao Liu Zihan Lin Zijian Liu Ping He Ying Feng Chunhua Wang Wei Wang Suhua Guan Qian Wang Ling Chen Pingchao Li Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants Emerging Microbes and Infections Adenovirus COVID-19 Omicron monovalent vaccine bivalent vaccine immunogenicity |
| title | Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants |
| title_full | Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants |
| title_fullStr | Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants |
| title_full_unstemmed | Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants |
| title_short | Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants |
| title_sort | comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late sars cov 2 variants |
| topic | Adenovirus COVID-19 Omicron monovalent vaccine bivalent vaccine immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2387447 |
| work_keys_str_mv | AT hengchunli comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT chenchenyang comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT liyin comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT wenmingliu comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT zhengyuanzhang comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT boliu comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT xinxinsun comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT wenhaoliu comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT zihanlin comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT zijianliu comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT pinghe comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT yingfeng comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT chunhuawang comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT weiwang comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT suhuaguan comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT qianwang comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT lingchen comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants AT pingchaoli comparativeimmunogenicityofmonovalentandbivalentadenovirusvaccinescarryingspikesofearlyandlatesarscov2variants |